Related Experiment Video
Updated: Mar 27, 2026

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System
Published on: October 20, 2023
Melanin-Concentrating Hormone (MCH): Role in REM Sleep and Depression
Pablo Torterolo1, Cecilia Scorza2, Patricia Lagos1
1Department of Physiology, School of Medicine, Universidad de la República Montevideo, Uruguay.
Abstract:
The melanin-concentrating hormone (MCH) is a peptidergic neuromodulator synthesized by neurons of the lateral sector of the posterior hypothalamus and zona incerta. MCHergic neurons project throughout the central nervous system, including areas such as the dorsal (DR) and median (MR) raphe nuclei, which are involved in the control of sleep and mood. Major Depression (MD) is a prevalent psychiatric disease diagnosed on the basis of symptomatic criteria such as sadness or melancholia, guilt, irritability, and anhedonia. A short REM sleep latency (i.e., the interval between sleep onset and the first REM sleep period), as well as an increase in the duration of REM sleep and the density of rapid-eye movements during this state, are considered important biological markers of depression. The fact that the greatest firing rate of MCHergic neurons occurs during REM sleep and that optogenetic stimulation of these neurons induces sleep, tends to indicate that MCH plays a critical role in the generation and maintenance of sleep, especially REM sleep. In addition, the acute microinjection of MCH into the DR promotes REM sleep, while immunoneutralization of this peptide within the DR decreases the time spent in this state. Moreover, microinjections of MCH into either the DR or MR promote a depressive-like behavior. In the DR, this effect is prevented by the systemic administration of antidepressant drugs (either fluoxetine or nortriptyline) and blocked by the intra-DR microinjection of a specific MCH receptor antagonist. Using electrophysiological and microdialysis techniques we demonstrated also that MCH decreases the activity of serotonergic DR neurons. Therefore, there are substantive experimental data suggesting that the MCHergic system plays a role in the control of REM sleep and, in addition, in the pathophysiology of depression. Consequently, in the present report, we summarize and evaluate the current data and hypotheses related to the role of MCH in REM sleep and MD.
Insights
Melanin-concentrating hormone (MCH) influences REM sleep and depressive behaviors. MCHergic system modulation offers potential therapeutic targets for sleep disorders and major depression.
Area of Science:
- Neuroscience
- Psychiatry
- Sleep Medicine
Background:
- Melanin-concentrating hormone (MCH) is a neuromodulator produced in the hypothalamus and zona incerta.
- MCH neurons project widely, influencing brain regions like the dorsal (DR) and median (MR) raphe nuclei, critical for sleep and mood regulation.
- Major Depression (MD) is characterized by mood disturbances and altered sleep patterns, including shortened REM sleep latency.
Purpose of the Study:
- To summarize and evaluate current data on the role of MCH in REM sleep regulation.
- To explore the involvement of MCH in the pathophysiology of Major Depression (MD).
Main Methods:
- Electrophysiological recordings and microdialysis techniques were employed.
- Optogenetic stimulation and peptide microinjections into specific brain regions were utilized.
- Pharmacological interventions, including antidepressant administration and MCH receptor antagonism, were investigated.
Main Results:
- MCH neuron activity peaks during REM sleep, and MCH stimulation promotes sleep, particularly REM sleep.
- MCH administration into the DR and MR induced depressive-like behaviors.
- Antidepressants and MCH receptor antagonists counteracted MCH-induced depressive-like effects in the DR.
- MCH was found to decrease the activity of serotonergic neurons in the DR.
Conclusions:
- The MCHergic system plays a significant role in the control of REM sleep.
- Experimental data strongly suggest MCH involvement in the pathophysiology of Major Depression.
- Targeting the MCH system presents a potential therapeutic avenue for both sleep disturbances and depression.
Related Concept Videos
REM Sleep Behavior Disorder
RBD is significantly associated with...
Management of Insomnia
Understanding Sleep
The circadian rhythm, a nearly 24-hour cycle, is deeply influenced by environmental light cues. Light exposure directly affects the hypothalamus, which in turn regulates...
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Sleep-Wake Cycles
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
Stages of Sleep
Before sleep begins, in wakefulness, the brain exhibits primarily beta waves, which are high in frequency and low in amplitude, indicating alertness...

